updat forecast estim feb
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jan
estim feb
price data feb
rate updat feb
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
root provid supportive-car product kidney
diseas cancer patient free cash flow hover sale
firm benefit massiv cost-cut improv
manufactur strong newer blockbust like prolia/xgeva
futur blockbust cholesterol drug repatha defend
wide moat eros due biosimilar brand
biolog vulner biosimilar innov
brand drug also steal share tougher label
reimburs affect anemia drug epogen
aranesp sinc safeti concern emerg launch
biosimilar retacrit weigh sale
neutropenia drug biosimilar competit
year key longer-act drug neulasta began see
declin key market due two biosimilar
launch effect brand competitor pois
continu erod enbrel share enbrel patent run
think biosimilar humira expect unit
state could pull sale tnf class
address headwind invest heavili
more-effici manufactur undertaken massiv
cost-cut program defend margin reinvest research
develop promot new area like cardiolog
also purchas oral immunolog drug otezla fit
well enbrel franchis larg biosimilar
portfolio low manufactur cost make viabl biosimilar
player well
newer drug pipelin key counter
biosimilar version older drug prolia osteoporosi xgeva
fractur prevent cancer patient see
billion peak sale kyproli -- acquir onyx
pois becom billion product multipl myeloma
repatha cholesterol-low look like biggest opportun
estim billion peak sale also
bullish posit migrain drug aimovig phase
asthma drug tezepelumab earli stage cancer program like
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
leader biotechnology-bas human therapeut
histor expertis renal diseas cancer supportive-car product
flagship drug includ red blood cell booster epogen aranesp immun
system booster neulasta enbrel inflammatori
diseas introduc first cancer therapeut vectibix
receiv approv bone-strengthen drug prolia/xgeva
acquisit onyx bolster firm therapeut oncolog
portfolio nexavar kyproli recent launch includ repatha
cholesterol-low aimovig migrain
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
sale declin fourth quarter share
repurchas counter top-lin pressur margin hit
higher research develop invest drive
non-gaap ep growth manag guidanc
revenu billion fit
forecast impli rel flat sale
portfolio full-year contribut celgen
immunolog drug otezla acquir novemb
non-gaap ep substanti
expect partli due higher-than-expect
oper expens well higher expens due
lower net cash book share beigen
result continu solid double-digit growth
osteoporosi drug prolia double-digit growth newer
nephrolog drug parsabiv migrain drug aimovig
encourag abil counter biosimilar
pressur maintain wide econom moat
addit acquisit otezla fit well
portfolio larg enbrel help expand
immunolog reach intern
biosimilar portfolio see excel sale growth
almost million sale amgevita
biosimilar humira kanjinti biosimilar herceptin
mvasi biosimilar avastin expect sale surpass
billion howev neulasta declin
fourth quarter due biosimilar competit dramat
declin full-year like larg
declin addit newest product
immun price pressur continu
headwind price pressur
aimovig repatha like stabil year
could see sever catalyst boost sale potenti
approv drug novel pipelin therapi
data could extend otezla use
mild psoriasi patient label also expand
includ scalp psoriasi year even growth
benefit approv europ decemb
strong uptak japan oncolog drug
key phase data nsclc combo data
keytruda data firm long-act bcma-
target bispecif multipl myeloma still
expect year although second half
key determin whether firm longer-act
bispecif technolog prove competit
modal emerg bcma market data heart
failur drug omecamtiv mecarbil also expect
fourth quarter although see higher-risk program
assum minim sales model phase data
astra asthma drug tezepelumab also
avail end year phase data posit
well compet dupix biolog treatment
maintain fair valu estim per share
think firm capabl averag top-lin growth
bottom-lin growth enbrel profit
share end signific cost-cut
non-gaap oper margin improv
peak nearli expect futur margin
remain near even addit invest
sell gener administr expens due
improv also give us increas confid
potenti biosimilar pipelin includ
nearli billion biosimilar sale
price power erod think enbrel sale
continu declin follow near-term benefit
price brand aranesp competit mircera
well epogen biosimilar launch weigh
declin begin extend
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
large-scal acquisit assum pre-tax cost
debt reflect normal
confid capabl defend
bottom line key period weak legaci
product cost-cut manufactur innov help
trim oper cost howev abil grow
heavili depend repatha abil move past payer
restrict well futur potenti restrict
aimovig migrain even osteoporosi
therefor assign diversifi biotech medium
repatha sale assumpt well futur oper
margin key assumpt behind fair valu
estim base-cas scenario assum adjust
oper margin declin remain near
royalti sale praluent revenu
repatha praluent peak billion
bull-cas scenario assum adjust oper
margin remain assum obtain
royalti sale praluent
revenu hit billion result fair
valu estim per share
bear-cas scenario assum adjust oper
margin declin low repatha sale
billion praluent royalti persist
difficulti payer reimburs also assum
addit hit sale begin
result potenti disrupt drug price reform
result fair valu estim per share
market sever blockbust biolog therapi
forecast biosimilar launch market
assum averag annual declin
neutropenia franchis neulasta
expect combin prolia/xgeva sale peak billion
forecast peak cholesterol-low sale billion
includ repatha sale well assum royalti
 praluent sale peak sale migrain drug
aimovig around billion peak global sale
osteoporosi drug even billion also see
newer cancer drug like blincyto imlyg smaller
opportun billion peak
assum cost capit rate systemat
risk surround share averag
cost equiti assumpt align capit cost
assumpt return equiti investor like
demand long run access
previous off-shore cash expect emphas
dividend share repurchas model slightli
declin gross debt near term note debt
level could easili increas undertak
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
oncolog immunolog market give
intang asset form foundat wide moat
one origin biotech launch innov
anemia neutropenia
begin epogen
longer-act product aranesp neulasta
launch firm decid acquir
immunex bring enbrel portfolio highli
profit biolog continu drive strong free cash
flow firm gener around sale expect
see steadi free cash flow margin level
return invest capit remain cost
capit forese futur
continu grow despit steadi regulatori
epogen aranesp sinc well biosimilar
competit anemia neutropenia drug
establish europ nascent gener
biosimilar pressur sever biolog
larg
manufactur difficulti cost clinic trial
product market creat high barrier entri
limit number entrant addit amgen
longer-act product aranesp neulasta help
defend biosimilar threat older product
also highli diversifi enbrel account
sale repatha otezla pois
top product sale strong growth
enbrel neutropenia drug counter epogen
aranesp headwind past year
osteoporosi cancer
indic reach blockbust statu
renal diseas drug sensipar onyx acquisit
multipl myeloma drug kyproli gener strong data
expand sale support european launch
competit like prevent signific uptak
see moat trend stabl think newli
launch product higher rate product
late-stag pipelin -- brand biosimilar -- allow
firm sustain strong roic new lower-cost
manufactur technolog aggress cost-cut
effort price volum pressur biosimilar
competit weigh heavili long-term margin
reimburs new competit brand
biosimilar biggest headwind moat
trend reimburs dialysi drug epogen bundl
dialysi product although contract
competit price margin pressur
product also among oldest --
profit -- market biolog mani among
first see biosimilar competit key patent
epogen neulasta expir
three product account top
line biosimilar competit europ mild
impact epogen sale focus
 brand neulasta shield
biosimilar competit neulasta sale
 howev epogen biosimilar
biosimilar neulasta coheru
launch earli overal expect
averag annual sale declin epogen
neutropenia franchis addit arthriti
psoriasi drug enbrel see high level new
competit assum double-digit sale declin
begin ahead humira biosimilar launch
howev regard pipelin product think amgen
turn corner think firm abl
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
top
line despit pressur current
blockbust histor high failur rate
pipelin particularli oncolog pipelin
decis return brodalumab
right astra due higher rate suicid also hit
late-stag pipelin howev cholesterol drug
repatha launch europ
despit slow start expect antibodi class
could gener billion peak sale
sanofi/regeneron praluent remain well ahead key
even approv cardiovascular
side effect could limit broad uptak drug
bone-form mechan action could complement
prolia migrain drug aimovig launch
could see billion peak potenti
also bullish abil compet
biosimilar market given firm effici manufactur
practic establish oncolog immunolog salesforc
regulatori legal expertis advanc pipelin
assum partner allergan hold
share global biosimilar market believ
manufactur improv could boost
biosimilar emerging-market opportun creat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
pipelin product sinc
launch prolia/xgeva cholesterol drug repatha
migrain drug aimovig reviv
enthusiasm firm research engin
obiosimilar market europ sinc
biosimilar larger impact
version epogen neulasta hit
acquisit decod give firm
abil identifi potenti new drug target valid
human genet
improv manufactur effici
benefit gross margin also could give firm
cost advantag nascent biosimilar market
alreadi launch two product europ
oth payoff billion acquisit
onyx highli depend success kyproli
johnson johnson/genmab darzalex
bcma-target therapi like strong
lack focu biotech peer
drug target larg market like osteoporosi
cardiolog specialti market like immunolog
oncolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
end held billion cash
billion debt expect compani gener
roughli billion free cash flow annual next
year combin one-tim repatri
off-shore cash end
suffici handl debt come due well
share-repurchas program billion repurchas
dividend program dividend increas
rise
biosimilar uptak remain biggest risk
neulasta epogen biosimilar
launch regulatori reimburs chang
could continu plagu aranesp epogen includ
medicar dialysi reimburs cut enbrel key
growth driver grow competit
rheumatoid arthriti psoriasi could weigh
firm market share price power evapor
overal price power could wane propos
medicar part reimburs
implement given firm relianc medicar
high proport sale addit sever
newer product enter highli competit market
prolia compet establish drug novarti
reclast cheaper gener bisphosphon vectibix
compet roch avastin eli lilli
kyproli lead proteasom inhibitor velcad
posit comparison fail differenti
kyproli first-lin set billion
acquisit onyx could prove expens repatha
shown signific abil reduc advers cardiovascular
event benefit may enough loosen payer
restrict limit patient access drug aimovig
also enter crowd market similar drug
entrant eager discount price gain share
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
mr robert bradwayceo/chairman board/
repres date owner name posit common share held report holder issuer
fidel manag research compani
share
fund
share
fund
assign amgen standard mark stewardship
firm engin struggl churn
promis drug candid sinc launch prolia/xgeva
believ new blood might benefici firm
product futur share perform sale
profit skyrocket reign ceo
chairman kevin sharer signific multipl
compress led flat perform firm share
tenur former presid bob bradway
replac sharer ceo may board chairman
start bradway advanc
sinc arriv vice presid oper
wish firm select someon longer
record pharmaceut industri
bradway year think
experi would particularli use
firm face steep biosimilar competit need
cohes strategi hope keep top-lin growth
posit territori said cfo david melin
appear make necessari cost cut achiev
left posit head research develop
posit sinc replac roger
perlmutt februari execut vice presid
global commerci oper anthoni hooper also
retir howev encourag progress
new leadership new head david rees
medic background serv sinc
new oper head murdo gordon join
bristol-my squibb formerli chief commerci offic
made sever shareholder-friendli move
recent histori share repurchas tender offer level
fair valu estim appear good use
cash quarterli dividend grew roughli annual
initi level continu grow
double-digit rate howev remain wari firm
compens polici reward execut easili
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
manipul ep growth instead return invest
capit board structur enough healthcare-rel
experi member former ceo
robert eckert phillip ceo greg garland
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
sustainalyt esg risk methodolog
point opportun pharma/biotech jan
sustainalyt
own
collabor broaden deepen
esg analysi incorpor environment social
govern factor valuat analysi
pharma focus
materi esg issu social realm think
firm expos esg risk morningstar
conclud valuation-affect esg risk brand
drug firm center price risk larg litig
provid comprehens evalu support
mostli wide moat rate industri
pharma morningstar
trump propos drug reimport look limit
potenti lower drug price dec
trump administr move allow drug import
canada look challeng implement
limit scope dont expect major chang
fair valu estim drug biotechnolog
industri view administr move driven
polit motiv anoth elect cycl draw
near rather major structur shift influenc drug
price continu view price power drug
strong central pillar support moat rate
larg drug biotechnolog compani
overal see under-valued name roch
biomarin lowest exposur esg-rel
strategi focu sever diseas lower price
pressur includ base case alreadi factor much
potenti headwind intern benchmark
price could test medicar part
biomarin global price strategi rare-diseas drug
well seriou natur condit limit futur
price litig risk despit high price tag
medicar exposur minim
import action propos
human servic juli propos rule
releas fda decemb dont view
plan major driver lower drug price think
implement chang would difficult
practic hard reconcil safeti provis
part feder track-and-trac system stop
counterfeit drug ensur enough drug-firm suppli low
price canada anoth concern drug firm could
limit distribut limit re-import also canada would
like support plan low drug price would
like face rise pressur support price
also like sanofi
valuat esg risk johnson johnson eli lilli look
least compel us base litig risk
valuat look under-valued
implement scope drug target potenti
re-import limit exclud drug biolog
inject drug drug subject fda risk evalu
mitig strategi rem drug group repres
core area focu new drug reach market
detail analysi price litig issu
top pharma name
coverag see januari
healthcar observ esg risk affect moat
congress support drug re-import past
safe implement propos limit
enact expect similar limit around
recent propos given complex distribut
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
differ drug label countri see poor
prospect wide use drug re-import
background polici propos
enact pleas see healthcar observ drug
price reform weigh valuat moat look
secur biotech industri look under-valued within
report highlight impact enact chang
drug payment increas discount
medicar part doughnut hole sale also review
depth drug polici propos council
econom advisor budget
amgen see mix neulasta biosimilar pressur
saw declin third-quart revenu due
gener biosimilar version
hyperparathyroid drug sensipar white
blood cell booster neulasta demand
growth newer product like osteoporosi drug prolia
sale cholesterol-low therapi repatha
remain double-digit territori uptak
biosimilar portfolio line bullish
saw declin encourag
abil manufactur improv larg off-set
pressur biosimilar midpoint higher
guidanc put firm high end prior
guidanc consist exist forecast
perform give us confid stabil
cash flow wide moat expect
signific chang fair valu estim rais
fair valu estim per share septemb
incorpor otezla acquisit good fit
enbrel amgevita
franchis otezla remain solid perform
throughout forecast particularli carv
nich mild moder psoriasi segment
current phase
focus key franchis repatha
sale growth encourag demand growth
even higher firm still face headwind price
reduct annual late year although sale
growth meet high expect continu
monitor potenti new competit threat space
still sensit point launch repatha
even medicin inclisiran reach market
schedul conveni twice year
administr profil versu month repatha
think physician wait cardiovascular outcom
data like prescrib inclisiran
anticip stem mix price
volum pressur howev sale prolia driven
demand immunolog drug enbrel driven price
higher expect sale new osteoporosi
drug even also higher expect
million quarter drug see launch europ
pipelin respiratori drug tezepelumab part
collabor astrazeneca phase data
asthma late recent enter phase copd
well phase ad also continu phase data
encourag could make competit regeneron
sanofi dupix launch asthma
oncolog kra inhibitor separ
phase studi lung colorect cancer
expect see addit data next year oct
mirati partner novarti report solid earli data
kra inhibitor think look
similar data sever
merck vaccin
phase also alreadi test combin
keytruda could broader efficaci kra
earlier-stag develop
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
complet review outlook psoriasi
remain secur innov counter price gener
headwind acceler
bristol sale otezla fair price
bristol-my squibb divest psoriasi drug otezla
billion repres price close
fair valu estim drug expect
major impact fair valu estim moat
firm deal appeas anti-trust
concern regul pend acquisit
celgen bristol follow announc divest
bristol guid close celgen deal late
slightli ahead previou guidanc think
updat guidanc reason
surpris potenti ownership
bristol pipelin psoriasi drug bm celgen
otezla caus anti-trust concern feder trade
commiss bristol face fire sale price otezla
continu view stronger two
psoriasi drug expect drug reach market
asset combin sever pipelin
perspect otezla add support
near-term growth project three-year compound
growth rate drug along exclus
least longer market also
strong presenc understand psoriasi market
develop commerci enbrel
mean rel smooth transit market otezla
longer term expect take share
otezla base stronger efficaci seen earli stage
studi drug offer conveni oral
administr addit expect
take share biolog psoriasi drug base easier
oral dose versu inject superior efficaci
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
